ClinicalTrials.gg
Not yet recruitingNCT07945665Updated Nov 18, 2026

Diagnostic Performance and Safety of Ragweed Pollen and Dog Dander Skin Prick Test Solutions

A Phase 3 interventional study of Ragweed Pollen Skin Prick Test Solution (3,500 DU/mL) and Dog Dander Skin Prick Test Solution (19,500 DU/mL) in Allergic Disorder, sponsored by Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.. Not yet recruiting at 3 sites in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Diagnostic

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
650
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 35 studies in Hypersensitivity with a site in China — 9 open to participants now, 9 under way, 1 of them phase 3. Hypersensitivity · China.

Planned enrollment
3rd of 20
650 · median 200
Started
2026
with 5 others
Phase 3
5 of 35
1 open now
Registered
35th of 35
by date

Among the 35 studies in Hypersensitivity with a site in China, this one is the 3rd largest by planned enrollment of the 20 interventional ones that give a count, is one of 6 that started in 2026, is one of 5 in phase 3, and was the 35th registered.

Hypersensitivity

1,059 studies on the registry are indexed under Hypersensitivity; 152 are open to participants now.

Browse Hypersensitivity studies →

Open to participants now

9 of the 35 studies in Hypersensitivity with a site in China are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 101 Hypersensitivity studies recruiting now, 38 (38%) set no upper age limit and 51 (50%) stop at 75 or younger; 55 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Hypersensitivity with a site in China, or all of them as a file.
02

Study summary

This multicenter, open-label, Phase III interventional study will evaluate the diagnostic performance and safety of ragweed pollen and dog dander skin prick test (SPT) solutions in adults in China with current or previous allergic diseases. Participants will undergo serum allergen-specific immunoglobulin E (sIgE) testing using the Thermo Fisher Scientific ImmunoCAP system. Each enrolled participant will receive one skin prick with ragweed pollen solution (3,500 DU/mL), dog dander solution (19,500 DU/mL), dog dander solution (39,000 DU/mL), and positive and negative controls. Wheal responses will be assessed 15-20 minutes after skin pricking. Diagnostic sensitivity and specificity will be determined separately for each test solution against the corresponding serum sIgE classification (cutoff ≥0.70 kUA/L). Safety will be assessed through adverse events, symptoms, vital signs, physical examinations, and laboratory tests.

03

Conditions studied

  • Allergic Disorder

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants aged 18-60 years, inclusive.
  2. Participants with a current or previous history of allergic diseases, such as allergic rhinitis, allergic conjunctivitis, or allergic asthma.
  3. Participants who are able to understand the study and voluntarily provide written .

Exclusion criteria

Exclusion Criteria:

  1. History of needle-related syncope or vasovagal reactions to the sight of blood.
  2. Pregnant or breastfeeding women.
  3. History of malignant tumors.
  4. Currently receiving beta-blockers or angiotensin-converting enzyme inhibitors and unable to discontinue treatment during the study.
  5. Currently experiencing a severe allergic reaction or having a history of severe allergic reactions, including generalized urticaria, severe or more serious acute asthma exacerbations, or anaphylactic shock.
  6. Use of topical or topical calcineurin inhibitors at the intended skin prick site within 7 days before SPT.
  7. Systemic use of antihistamines or antihistamine-containing combination medications before SPT, with a discontinuation period not exceeding five elimination half-lives of the antihistamine.
  8. Use of short-acting systemic corticosteroids within 2 days, intermediate-acting systemic corticosteroids within 5 days, or long-acting systemic corticosteroids within 12 days before SPT.
  9. Systemic use of within 14 days before SPT.
  10. Use of phenothiazine antipsychotics within 10 days or imipramine-class antidepressants within 21 days before SPT.
  11. Treatment with dupilumab or similar agents within 3 months before SPT.
  12. Treatment with omalizumab or similar agents within 5 months before SPT.
  13. Photochemotherapy on the volar surfaces of both forearms within 30 days before SPT.
  14. Skin infection, dermatitis, trauma, scarring, pigmentation, or other pathological changes at the intended volar forearm test site that, in the investigator's judgment, may interfere with SPT interpretation.
  15. Positive skin scratch test for dermographism during screening.
  16. Participation in another drug clinical trial with administration of an product within 1 month before screening, or less than five elimination half-lives since the last administration of that investigational product, whichever period is longer.
  17. Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
650 participants (estimated)

Study arms

  • Experimental
    Skin Prick Test Group

    All enrolled participants receive ragweed pollen SPT solution (3,500 DU/mL), dog dander SPT solution (19,500 DU/mL), dog dander SPT solution (39,000 DU/mL), and positive and negative control solutions during the same test session.

    Diagnostic Test: Ragweed Pollen Skin Prick Test Solution (3,500 DU/mL) · Diagnostic Test: Dog Dander Skin Prick Test Solution (19,500 DU/mL) · Diagnostic Test: Dog Dander Skin Prick Test Solution (39,000 DU/mL)

Interventions

  • Diagnostic testRagweed Pollen Skin Prick Test Solution (3,500 DU/mL)

    One drop applied to the volar forearm, followed by a single skin prick; wheal assessed 15-20 minutes later.

  • Diagnostic testDog Dander Skin Prick Test Solution (19,500 DU/mL)

    One drop applied to the volar forearm, followed by a single skin prick; wheal assessed 15-20 minutes later.

  • Diagnostic testDog Dander Skin Prick Test Solution (39,000 DU/mL)

    One drop applied to the volar forearm, followed by a single skin prick; wheal assessed 15-20 minutes later.

06

What researchers measure

Primary outcomes

  1. Sensitivity: Ragweed Pollen (3,500 DU/mL)

    Percentage of participants with a positive SPT result among participants with serum ragweed sIgE ≥0.70 kUA/L by ImmunoCAP (w1). An SPT is positive when maximum wheal diameter is ≥3 mm, provided control validity criteria are met.

    Time frame: 15-20 minutes after skin prick testing (Day 1).

  2. Specificity: Ragweed Pollen (3,500 DU/mL)

    Percentage of participants with a negative SPT result among participants with serum ragweed sIgE \<0.70 kUA/L by ImmunoCAP (w1). An SPT is negative when maximum wheal diameter is \<3 mm, provided control validity criteria are met.

    Time frame: 15-20 minutes after skin prick testing (Day 1).

  3. Sensitivity: Dog Dander (19,500 DU/mL)

    Percentage of participants with a positive SPT result among participants with serum dog dander sIgE ≥0.70 kUA/L by ImmunoCAP (e5). An SPT is positive when maximum wheal diameter is ≥3 mm, provided control validity criteria are met.

    Time frame: 15-20 minutes after skin prick testing (Day 1).

  4. Specificity: Dog Dander (19,500 DU/mL)

    Measure Description: Percentage of participants with a negative SPT result among participants with serum dog dander sIgE \<0.70 kUA/L by ImmunoCAP (e5). An SPT is negative when maximum wheal diameter is \<3 mm, provided control validity criteria are met.

    Time frame: 15-20 minutes after skin prick testing (Day 1).

  5. Sensitivity: Dog Dander (39,000 DU/mL)

    Percentage of participants with a positive SPT result among participants with serum dog dander sIgE ≥0.70 kUA/L by ImmunoCAP (e5). An SPT is positive when maximum wheal diameter is ≥3 mm, provided control validity criteria are met.

    Time frame: 15-20 minutes after skin prick testing (Day 1).

  6. Specificity: Dog Dander (39,000 DU/mL)

    Percentage of participants with a negative SPT result among participants with serum dog dander sIgE \<0.70 kUA/L by ImmunoCAP (e5). An SPT is negative when maximum wheal diameter is \<3 mm, provided control validity criteria are met.

    Time frame: 15-20 minutes after skin prick testing (Day 1).

Secondary outcomes

  1. Adverse Events

    Number and percentage of participants experiencing adverse events, adverse drug reactions, serious adverse events, serious adverse drug reactions, and adverse events leading to withdrawal, by test solution as applicable.

    Time frame: From first skin prick administration (Day 1) through the final study visit (approximately 24 hours +4 hours after testing), with follow-up of unresolved events as required by protocol.

  2. Changes in Vital Signs from Baseline

    Changes in vital signs from baseline will be assessed, including body temperature (°C), systolic and diastolic blood pressure (mmHg), and pulse rate (beats/min). Descriptive statistics, including mean, median, standard deviation, quartiles, minimum, and maximum, will be presented.Changes in vital signs will be summarized using cross-tabulations. Clinically significant abnormalities will be listed.

    Time frame: At screening, within 2 hours before SPT, 1 hour ±10 minutes after SPT, and 24 hours ±4 hours after SPT.

  3. Changes in Physical Examination Findings from Baseline

    Changes in physical examination findings from baseline will be assessed, including skin and mucosa, lymph nodes, head and neck, chest, abdomen, and spine and extremities. Changes in examination findings will be summarized using cross-tabulations. Clinically significant abnormalities will be listed.

    Time frame: At screening and on Day 2 of the study or at early termination.

  4. Changes in Hematology Parameters from Baseline

    Changes in hematology parameters from baseline will be assessed, including white blood cell count; absolute and percentage counts of neutrophils, lymphocytes, monocytes, eosinophils, and basophils; red blood cell count; hemoglobin; and platelet count. Units of measurement will follow the laboratory reports. Quantitative results will be summarized using the mean, median, standard deviation, quartiles, minimum, and maximum. Changes in clinical assessment categories will be summarized using cross-tabulations. Clinically significant abnormalities will be listed.

    Time frame: At screening and on Day 2 of the study or at early termination.

  5. Changes in Urinalysis Parameters from Baseline

    Changes in urinalysis parameters from baseline will be assessed, including urine bilirubin, glucose, ketones, protein, occult blood, and leukocytes or leukocyte esterase. Results will be summarized according to the categories reported by the laboratory. Changes in results will be summarized using cross-tabulations. Clinically significant abnormalities will be listed.

    Time frame: At screening and on Day 2 of the study or at early termination.

07

Study locations

3 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jun 2027, 6 months later.

Of 32 industry-sponsored phase 3 interventional studies under Hypersensitivity, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 34. This study's planned 6 months is below that.

Counting every sponsor, half of 42 studies reached it within 23 months; a quarter within 10 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2026
First posted
Nov 18, 2026
StartEst.
Nov 11, 2026
Primary completionEst.
Jun 1, 2027
CompletionEst.
Oct 1, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07945665
Lead sponsor
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Nov 11, 2026 (estimated)
Primary completion
Jun 1, 2027 (estimated)
Completion
Oct 1, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Wang Jiazheng
Contact
wangjiazheng@wolwobiotech.com
+8615800536923

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion